Abbott Laboratories has won a legal case claiming its Similac infant formula caused the death of a baby from necrotizing ...

The win is Abbott’s third in a row in federal court in Chicago where hundreds of cases over specialized formulas for preterm ...

Abbott stock skidded early Wednesday after the health giant reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales.

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults ...

According to Benzinga Pro, Abbott Laboratories's peer group average for short interest as a percentage of float is 5.57%, ...

Abbott Laboratories (ABT) stock has drifted slightly lower this month, with shares showing a 7% drop over the past month.

Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the ...

Abbott Laboratories Inc. convinced a federal judge that there wasn’t a feasible alternative design to a form of infant formula that parents said caused a fatal disease to their preterm child.

Abbott trimmed its earnings forecast as the Trump administration launched an investigation into medical device imports that could trigger new tariffs.

The fate of hundreds of pending cases against Abbott and Mead Johnson hang in the balance with the latest dismissal.

The court said D.B.'s parents could not meet the threshold for a product liability claim under Louisiana's Products Liability ...